DOCSLIB.ORG

Drug Screen Listing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Screen Listing DRUG SCREEN LISTING The following are detected by a general urine drug screen. Abacavir Acebutolol Acetaminophen Acetohexamide Acyclovir Alprazolam Alprazolam metabolite (alpha-Hydroxyalprazolam) Alprenolol Amantadine Ambroxol Amiloride Amiodarone Amitriptyline Amlodipine Amobarbital as BAR Amoxapine Amphetamine Aprobarbital as BAR Aripiprazole Aripiprazole metabolite (dehydro-aripiprazole) Atenolol Atomoxetine Atorvastatin Atropine Baclofen Barbital as BAR Bendiocarb Benzocaine Benztropine Betaxolol Bisoprolol Bromazepam Bromocriptine Brompheniramine Bupivacaine Buprenorphine Buprenorphine metabolite (norbuprenorphine) Bupropion Buspirone Butabarbital as BAR Butalbital as BAR BZP (1-benzylpiperazine) Caffeine Captopril Carbamazepine Carbamazepine metabolite (10,11-dihydro-10,11- Page 1 of 13 dihydroxycarbamazepine) Carbamazepine metabolite (carbamazepine-10,11-epoxide) Carisoprodol Carvedilol Cathinone Cetirizine Chlordiazepoxide Chlordiazepoxide metabolite (norchlordiazepoxide) Chloroquine Chlorpheniramine Chlorpromazine Chlorpropamide Chlorprothixene Cilazapril Cimetidine Citalopram Citalopram metabolite (desmethylcitalopram) Clenbuterol Clobazam Clobazam metabolite (desmethylclobazam) Clomipramine Clomipramine metabolite (desmethylclomipramine) Clonazepam Clonazepam metabolite (7-Aminoclonazepam) Clonidine Clozapine Clozapine metabolite (clozapine-N-oxide) Clozapine metabolite (norclozapine) Cocaine Cocaine metabolite (benzoylecgonine) Cocaine metabolite (cocaethylene) Cocaine metabolite (ecgoninemethylester) Cocaine metabolite (ethylecgonine) Codeine Codeine metabolite (norcodeine) Colchicine Cotinine Cyclobenzaprine Cyclopentobarbital as BAR Desipramine Dextromethorphan Diazepam Diazepam metabolite (nordiazepam) Dicyclomine Digoxin Dihydrocodeine Dihydroergotamine Diltiazem Diphenhydramine Dipyridamole Page 2 of 13 Disopyramide Dobutamine Domperidone Donepezil Doxepin Doxepin metabolite (nordoxepin) Doxylamine Duloxetine Emetine Enalapril Epinephrine Eprosartan Erythromycin Esmolol Estazolam Ethanol as ETOU Etomidate Famotidine Felodipine Fenfluramine Fentanyl Fentanyl metabolite (norfentanyl) Flecainide Fluconazole Flumazenil Flunitrazepam Flunitrazepam metabolite (7-Aminoflunitrazepam) Fluoxetine Fluoxetine metabolite (norfluoxetine) Flupentixol Fluphenazine Flurazepam Flurazepam metabolite (2-Hydroxyethylflurazepam) Flurazepam metabolite (N-desalkylflurazepam) Fluvoxamine Gabapentin Galantamine Gliclazide Glimepiride Glipizide Glyburide Granisetron Haloperidol Heroin Heroin metabolite (6-O-Monoacetylmorphine) Hydralazine Hydrocodone Hydrocortisone Hydromorphone Hydromorphone metabolite (hydromorphone-3-glucuronide) Page 3 of 13 Hydroxychlorquine Hydroxyzine Imipramine Irbesartan Ketamine Ketoprofen Ketorolac Labetalol Lamotrigine Levamisole Levetiracetam Lidocaine Lisinopril Loperamide Loratadine Lorazepam Losartan Loxapine Maprotiline MDA (3,4-methylenedioxyamphetamine) MDEA (3,4-methyledioxyethylamphetamine) MDMA (3,4-methylenedioxymethamphetamine) MDPV (Methylenedioxypyrovalerone) Meclizine Medazepam Meloxicam Meperidine Meperidine metabolite (normeperidine) Mepivacaine Mephedrone Meprobamate Mescaline Mesoridazine Metformin Methadone Methadone metabolite (EDDP) Methamphetamine Methaqualone Methcathinone Methedrone Methocarbamol Methotrimeprazine Methoxyverapamil Methylone Methylphenidate Metoclopramide Metoprolol Metronidazole Mexiletine Mianserin Page 4 of 13 Midazolam Midazolam metabolite (alpha-Hydroxymidazolam) Midodrine Minoxidil Mirtazapine Moclobemide Morphine Morphine metabolite (morphine-3-D-glucuronide) Morphine metabolite (normorphine) Nadolol Nalbuphine Nalorphine Naltrexone Nandrolone Nateglinide Nefazodone Nicardipine Nicotine Nifedipine Nimodipine Nitrazepam Nitrazepam metabolite (7-Aminonitrazepam) Nomifensine Nortriptyline Noscapine Olanzapine Ondansetron Orphenadrine Oxaprozin Oxazepam Oxcarbazepine Oxcarbazepine metabolite (10-hydroxycarbazepine) Oxprenolol Oxybutynin Oxycodone Oxycodone metabolite (noroxycodone) Oxymorphone Oxymorphone metabolite (noroxymorphone) Papaverine Paroxetine Pentazocine Pentobarbital as BAR Pentoxifylline Perindopril Perphenazine Phenazepam Phenazopyridine Phencyclidine Phenelzine Pheniramine Page 5 of 13 Phenobarbital as BAR Phentermine Phenylephrine Phenyltoloxamine Phenytoin Physostigmine Pilocarpine Pimozide Pindolol Pioglitazone Piroxicam Pizotifen PMMA (para-methoxy-N-methylamphetamine) Prazepam Prazosin Pregabalin Primaquine Primidone Procainamide Procainamide metabolite (N-acetylprocainamide) Procaine Prochlorperazine Procyclidine Promazine Promethazine Propafenone Propoxyphene Propoxyphene metabolite (norpropoxyphene) Propranolol Protriptyline Pseudoephedrine Pseudoephedrine metabolite (norpseudoephedrine) Psilocin Pyrilamine Quetiapine Quetiapine metabolite (7-OH-quetiapine sulfoxide) Quetiapine metabolite (quetiapine sulfoxide) Quinapril Quinidine Ramipril Ranitidine Repaglinide Reserpine Rifampicin Risperidone Risperidone metabolite (9-Hydroxyrisperidone) Rizatriptan Ropivacaine Rosiglitazone Salbutamol Page 6 of 13 Scopolamine Secobarbital as BAR Selegiline Sertraline Sertraline metabolite (norsertraline) Sildenafil Sotalol Strychnine Sulindac Sufentanyl Sumatriptan Synephrine Tamoxifen Tapentadol Telmisartan Temazepam Tenocixam Terazosin Terbinafine Terbutaline Terfenadine Tetracaine Tetrahydrocannabinol metabolite (THC-COOH) as CAN TFMPP (1-(3-trifluoromethylphenyl)-piperazine) Theobromine Theophylline Thioridazine Timolol Tizanidine Tocainide Tolazamide Tolbutamide Tolterodine Tramadol Tramadol metabolite (O-desmethyltramadol) Tranylcypromine Trazodone Triamterene Triazolam Triazolam metabolite (alpha-Hydroxytriazolam) Trifluperazine Trihexyphenidyl Trimethoprim Trimipramine Trimipramine metabolite (desmethyltrimipramine) Tripelennamine Triprolidine Valsartan Vardenafil Varenicline Page 7 of 13 Venlafaxine Venlafaxine metabolite (O-desmethylvenlafaxine) Verapamil Verapamil metabolite (norverapamil) Vigabatrin Warfarin Warfarin metabolite (7-hydroxywarfarin) Yohimbine Ziprasidone Zolpidem Zopiclone Zuclopenthixol ************************************************************ The general drug screen does not include, salicylate, NSAIDs, steroids, pesticides and antibiotics. JANUARY 16, 2014 Page 8 of 13 Amphetamine Crossreactivity d-amphetamine 104% d-methamphetamine 100% 3,4-methylenedioxymethamphetamine (MDMA) 196% 3,4-methylenedioxyamphetamine (MDA) 116% 3,4-methylenedioxyethylamphetamine (MDEA) 172% phenylpropanolamine 0% ephedrine 1% pseudoephedrine 1% d,I-amphetamine 88% d,I-methamphetamine 77% p-methoxyamphetamine (PMA) 24% p-methoxymethamphetamine (PMMA) 100% N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) 121% 3,4-methylenedioxyphenyl-2-butanamine (BDB) 76% I-methamphetamine 18% I-amphetamine 1% phenteramine 3% Barbiturate Crossreactivity secobarbital 100% cyclopentobarbital 115% aprobarbital 80% butalbital 92% butabarbital 78% pentobarbital 66% phenobarbital 83% amobarbital 109% talbutal 160% Page 9 of 13 barbital 18% Benzodiazepines Crossreactivity estazolam 239% alprazolam 220% triazolam 217% delorazepam 197% flurazepam 195% N-desalkylflurazepam 173% nordiazepam 173% alpha-hydroxyalprazolam 167% alpha-hydroxytriazolam 155% diazepam 154% lormetazepam 137% alpha-hydroxymidazolam 120% oxazepam 125% medazepam 118% prazepam 116% lorazepam 115% flunitrazepam 109% bromazepam 104% halazepam 101% nitrazepam 100% 7-aminoflunitrazepam 99% 7-aminoclonazepam 96% temazepam 93% 7-aminonitrazepam 83% clorazepate 75% clonazepam 71% clobazam 59% demoxepam 19% chlordiazepoxide 16% Page 10 of 13 haloperidol 0% citalopram 0% Cannabinoids Crossreactivity delta-9-THC-COOH, major metabolite 100% 8-hydroxy-delta-9-THC, metabolite 3% 11-hydroxy-delta-9-THC, metabolite 43% 8,11-dihydroxy-delta-9-THC, metabolite 8% delta-9-THC 11% delta-9-THC-COOH-glucuronide 78% cannabinol 3% cannabidiol 0% delta-8-THC-COOH 125% Cocaine Crossreactivity benzoylecgonine, major metabolite 100% cocaine 54% ecgonine, metabolite 1% ecgonine methyl ester, metabolite 0% cocaethylene 57% LSD Crossreactivity Page 11 of 13 LSD 100% 2-oxo-3-hydroxy-LSD, metabolite 1% Methadone Crossreactivity methadone 100% methadone major metabolite (EDDP) 0% methadone minor metabolite (EMDP) 0% Opiate Crossreactivity morphine 100% codeine 125% 6-acetylmorphine 81% dihydrocodeine 50% morphine-3-glucuronide 81% morphine-6-glucuronide 47% hydrocodone 48% hydromorphone 57% hydromorphone-3-glucuronide 75% oxycodone 3% oxymorphone 2% diacetylmorphine 53% methadone 0% meperidine 0% Page 12 of 13 Oxycodone Crossreactivity oxycodone 100% oxymorphone 103% noroxycodone 0% noroxymorphone 0% 6-MAM 0% codeine 0% dihydrocodeine 0% heroin 0% hydrocodone 0% hydromorphone 0% levorphanol 0% morphine 0% morphine-glucuronide 0% naloxone 0% naltrexone 0% norcodeine 0% normorphine 0% pentazocine 0% tramadol 0% Page 13 of 13 .
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • The Postmortem Distribution of Vardenafil (Levitra | in an Aviation
    Journal of Analytical Toxicology, Vol. 31, July/August 2007 The Postmortem Distribution of Vardenafil (Levitra| in an Aviation Accident Victim with an Unusually High Blood Concentration* Robert D. Johnson ~, Russell J. Lewis, and Mike K. Angler Downloaded from https://academic.oup.com/jat/article/31/6/328/682815 by guest on 27 September 2021 Civil Aerospace Medical Institute, Federal Aviation Administration, Analytical Toxicology and Accident Research Laboratory, AAM-610, CAMI Building, 6500 S. MacArthur Blvd., Oklahoma City, Oklahoma 73169-6901 I Abstract phodiesterase type 5 enzyme (PDE5) found predominantly in the penile corpus cavernosum (2-7). Vardenafil (tevitra) is one of the most widely prescribed Vardenafil undergoes hepatic metabolism, producing the treatments for erectile dysfunction. This report presents a active desethyl metabolite M1. M1 contributes to the ob- rapid and reliable method for the identification and quantification served pharmacological effects provided by vardenafil, as M1 of vardenafil in postmortem fluids and tissues, applies this method exhibits approximately 30% of the potency of the parent to a postmortem case, and describes the distribution of vardenafil in various fluids and tissues.This procedure utilizes sildenafil-d8, drug (1). Under steady-state conditions, the plasma concen- which is structurally closely related to vardenafil, as an tration of M1 is approximately 26% of that seen for vardenafil internal standard for more accurate and reliable quantitation. (1). After oral administration of vardenafil, peak plasma con- The method incorporates solid-phaseextraction and liquid centrations are obtained within 30-60 min (1). Vardenafil chromatography-tandem mass spectrometry (MS) and and its active metabolite have a terminal half-life of approx- MS-MS-MS utilizing an atmospheric pressure chemical imately 4-5 h (1).
    [Show full text]
  • Use of Human Plasma Samples to Identify Circulating Drug Metabolites That Inhibit Cytochrome P450 Enzymes
    1521-009X/44/8/1217–1228$25.00 http://dx.doi.org/10.1124/dmd.116.071084 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1217–1228, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes Heather Eng and R. Scott Obach Pfizer Inc., Groton, Connecticut Received April 19, 2016; accepted June 3, 2016 ABSTRACT Drug interactions elicited through inhibition of cytochrome P450 fractions were tested for inhibition of six human P450 enzyme (P450) enzymes are important in pharmacotherapy. Recently, activities (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and greater attention has been focused on not only parent drugs CYP3A4). Observation of inhibition in fractions that correspond to inhibiting P450 enzymes but also on possible inhibition of these the retention times of metabolites indicates that the metabolite Downloaded from enzymes by circulating metabolites. In this report, an ex vivo method has the potential to contribute to P450 inhibition in vivo. Using whereby the potential for circulating metabolites to be inhibitors of this approach, norfluoxetine, hydroxyitraconazole, desmethyldiltia- P450 enzymes is described. To test this method, seven drugs and zem, desacetyldiltiazem, desethylamiodarone, hydroxybupropion, their known plasma metabolites were added to control human erythro-dihydrobupropion, and threo-dihydrobupropion were iden- plasma at concentrations previously reported to occur in humans
    [Show full text]
  • Aerobic Treatment of Selective Serotonin Reuptake Inhibitors in Landfill Leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3
    Bergersen et al. Environmental Sciences Europe (2015) 27:6 DOI 10.1186/s12302-014-0035-0 RESEARCH Open Access Aerobic treatment of selective serotonin reuptake inhibitors in landfill leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3 Abstract Background: Pharmaceuticals used in human medical care are not completely eliminated in the human body and can enter the municipal sewage sludge system and leachate water from landfill both as the parent compound and as their biologically active metabolites. The selective serotonin reuptake inhibitors (SSRIs) have a large potential for unwanted effects on nontarget organisms in the environment. Leachates from active or old closed landfills are often treated with continuous stirring and simple aeration in a pond/lagoon before infiltration into the environment. The aim of this work was to simulate the reduction of five SSRIs (citalopram, fluoxetine, paroxetine, sertraline and fluvoxamine) and three of their metabolites (desmethylcitalopram, didesmethylcitalopram and norfluoxetine) during aerobic treatment of leachate from landfills. This landfill leachate-simulation experiment was performed to see what happens with the pharmaceuticals during aerated treatment and continuous stirring of landfill leachate for 120 h. It is important to establish whether different pollutants such as pharmaceuticals can be removed (oxidized or otherwise degraded) or not before infiltration into the environment. Results: All the SSRIs had a significant concentration reduction during the aeration treatment process. Total SSRI concentrations were reduced significantly during aerobic treatment, and the individual SSRIs were reduced by 89% to 100% after 120 h. Among the high-concentration samples, fluoxetine (10 mg L−1) was the least degraded with 93% concentration reduction.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column
    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Vardenafil Better Choice for Premature Ejaculation
    August 15, 2005 • www.familypracticenews.com Men’s Health 47 Vardenafil Better Choice for Premature Ejaculation BY ROBERT FINN (24%) of the men and was secondary (in On a self-rating scale of 0-8, where 0 Center but is now at the University of San Francisco Bureau most cases to erectile dysfunction) in the means PE almost never, 4 means PE about Hamburg. remaining 26 men (77%). half the time, and 8 means PE almost al- Self-ratings of sexual satisfaction, on a 0- S AN A NTONIO — Vardenafil improved After a 4-week run-in period, 17 men ways, the mean score was 6.14 at baseline, 5 scale, where 0 means not at all satisfied premature ejaculation more than sertra- were given 10-mg vardenafil 10 minutes 4.28 with sertraline, and 3.2 with varde- and 5 means extremely satisfied, averaged line, Frank Sommer, M.D., reported at the before intercourse for 6 weeks. The other nafil. 1.4 at baseline, 3.2 with sertraline, and 4.2 annual meeting of the American Urolog- 17 received 50 mg of sertraline 4 hours be- IVELT, as measured by a stopwatch, with vardenafil. In addition, the partners’ ical Association. fore intercourse. averaged 0.54 minutes at baseline, 2.87 sexual satisfaction showed significant in- Both vardenafil (Levitra), a phosphodi- After a 1-week washout period, the men minutes with sertraline, and 5.23 minutes creases for sertraline and even more so for esterase-5 inhibitor, and sertraline (Zoloft), who had been receiving sertraline with vardenafil, reported Dr. Sommer, vardenafil.
    [Show full text]
  • LEVITRA (Vardenafil Hcl) Tablets
    LEVITRA (vardenafil HCl) Tablets DESCRIPTION LEVITRA® is an oral therapy for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5- methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4- ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula: O O HN N x HCl x 3H2O N N O S O N N Vardenafil HCl is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water. LEVITRA is formulated as orange, round, film-coated tablets with "BAYER" cross debossed on one side and "2.5", "5", "10", and "20" on the other side corresponding to 2.5 mg, 5 mg, 10 mg, and 20 mg of vardenafil, respectively. In addition to the active ingredient, vardenafil HCl, each tablet contains microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide. CLINICAL PHARMACOLOGY Mechanism of Action Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection.
    [Show full text]
  • Screening of Pharmaceuticals in San Francisco Bay Wastewater
    Screening of Pharmaceuticals in San Francisco Bay Wastewater Prepared by Diana Lin Rebecca Sutton Jennifer Sun John Ross San Francisco Estuary Institute CONTRIBUTION NO. 910 / October 2018 Pharmaceuticals in Wastewater Technical Report Executive Summary Previous studies have shown that pharmaceuticals are widely detected in San Francisco Bay, and some compounds occasionally approach levels of concern for wildlife. In 2016 and 2017, seven wastewater treatment facilities located throughout the Bay Area voluntarily collected wastewater samples and funded analyses for 104 pharmaceutical compounds. This dataset represents the most comprehensive analysis of pharmaceuticals in wastewater to date in this region. On behalf of the Regional Monitoring Program for Water Quality in San Francisco Bay (RMP), the complete dataset was reviewed utilizing RMP quality assurance methods. An analysis of influent and effluent information is summarized in this report, and is intended to inform future monitoring recommendations for the Bay. Influent and effluent concentration ranges measured were generally within the same order of magnitude as other US studies, with a few exceptions for effluent. Effluent concentrations were generally significantly lower than influent concentrations, though estimated removal efficiency varied by pharmaceutical, and in some cases, by treatment type. These removal efficiencies were generally consistent with those reported in other studies in the US. Pharmaceuticals detected at the highest concentrations and with the highest frequencies in effluent were commonly used drugs, including treatments for diabetes and high blood pressure, antibiotics, diuretics, and anticonvulsants. For pharmaceuticals detected in discharged effluent, screening exercises were conducted to determine which might be appropriate candidates for further examination and potential monitoring in the Bay.
    [Show full text]
  • Determination of Antidepressants in Human Plasma by Modified Cloud
    pharmaceuticals Article Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry El˙zbietaGniazdowska 1,2 , Natalia Korytowska 3 , Grzegorz Kłudka 3 and Joanna Giebułtowicz 3,* 1 Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland; [email protected] 2 Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Zwirki˙ i Wigury, 02-091 Warsaw, Poland 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland; [email protected] (N.K.); [email protected] (G.K.) * Correspondence: [email protected] Received: 5 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Cloud-point extraction (CPE) is rarely combined with liquid chromatography coupled to mass spectrometry (LC–MS) in drug determination due to the matrix effect (ME). However, we have recently shown that ME is not a limiting factor in CPE. Low extraction efficiency may be improved by salt addition, but none of the salts used in CPE are suitable for LC–MS. It is the first time that the influences of a volatile salt—ammonium acetate (AA)—on the CPE extraction efficiency and ME have been studied. Our modification of CPE included also the use of ethanol instead of acetonitrile to reduce the sample viscosity and make the method more environmentally friendly. We developed and validated CPE–LC–MS for the simultaneous determination of 21 antidepressants in plasma that can be useful for clinical and forensic toxicology. The selected parameters included Triton X-114 concentration (1.5 and 6%, w/v), concentration of AA (0, 10, 20 and 30%, w/v), and pH (3.5, 6.8 and 10.2).
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]